Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-16. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
==== World Health Organization ==== On January 22, 2026, President Donald Trump completed the withdrawal of the United States from the World Health Organization (WHO), a specialized agency of the United Nations, a year after he signed Executive Order 14155 on January 20, 2025. As announced by the Department of Health and Human Services, the United States officially exited the organization, ending its 78-year membership and halting all U.S. funding and participation in the WHO's governance and activities. Although the organization hoped for a reconsideration the day after Trump's executive order, the administration continued with the decision. The administration justified the withdrawal by citing concerns about the WHO's handling of global health emergencies, including the COVID-19 pandemic, its resistance to reforms, and its failure to operate independently from inappropriate political influence of other WHO member states. In a joint statement by Secretary of State Marco Rubio and Secretary of Health and Human Services Robert F. Kennedy Jr., they said that the WHO "tarnished and trashed everything that America has done for it" and it "abandoned its core mission and acted repeatedly against the interests of the United States", including the failure to "hand over the American flag that hung in front of it". The United States still owes outstanding dues to the WHO from 2024 to 2025, raising questions about the legality and financial implications of the exit.
== Medicinal uses == The bark extracts of Vachellia leucophloea are used in Pakistani traditional medicine as an astringent, a bitter, a thermogenic, a styptic, a preventive of infections, an anthelmintic, a vulnerary, a demulcent, an expectorant, an antipyretic, an antidote for snake bites and in the treatment of bronchitis, cough, vomiting, wounds, ulcers, diarrhea, dysentery, internal and external hemorrhages, dental caries, stomatitis, and intermittent fevers and skin diseases. An ethanolic extract ointment has shown marked wound healing activity in trials.
== Modifications == The ribonucleosides adenosine, cytidine, guanosine, and uridine are all derivatives of β-d-ribofuranose. Metabolically important species that include phosphorylated ribose include ADP, ATP, coenzyme A, and NADH. cAMP and cGMP serve as secondary messengers in some signaling pathways and are also ribose derivatives. The ribose moiety appears in some pharmaceutical agents, including the antibiotics neomycin and paromomycin.
As the moral authority of Barre's government was gradually eroded, many Somalis became disillusioned with life under military rule. By the mid-1980s, resistance movements supported by Ethiopia's communist Derg administration had sprung up across the country. Barre responded by ordering punitive measures against those he perceived as locally supporting the guerrillas, especially in the northern regions. The clampdown included bombing of cities, with the northwestern administrative centre of Hargeisa, a Somali National Movement (SNM) stronghold, among the targeted areas in 1988. The clampdown initiated by Barre's government extended its reach beyond the initial bombings in the north to encompass various regions across the country. This reproduction of aggressive strategies aimed at stifling dissent and retaining authority over the populace was a hallmark of the government's repressive actions in the South. One of the most notable instances occurred in 1991, when Barre's regime initiated a ruthless aerial assault that led to the deaths of numerous individuals in the town of Beledwene, situated in southern Somalia. Another notable instance of Barre's repressive policies occurred in the city of Baidoa, which earned the nickname 'the city of death' due to the events that unfolded there during the famine and civil war. Hundreds of thousands of individuals lost their lives as a consequence of governmental strategies specifically aimed at the Rahanweyn community residing in these areas.
For diabatically enhanced classical events, at 24 hours prior to the onset of CAD, a prominent 250-mb jet extends from southwest to northeast across eastern North America. A general area of troughing is present at the 500- and 250-mb levels west of the jet. The parent high-pressure system is centered over the upper Midwest beneath the 250-mb jet entrance region, setting up conditions for CAD east of the Rocky Mountains. For dry onset classical events, the 250-mb jet is weaker and centered farther east relative to the diabatically enhanced classical events. The jet also does not extend as far southwest compared to diabatically enhanced classical CAD events. The center of the high-pressure system is farther east, so ridging extends southward into the south-central eastern United States. Although both types of classical events begin differently, their results are very similar.
Sources: en.wikipedia.org
Just under 20% of the land area of Lower Saxony is designated as nature parks, i.e.: Dümmer, Elbhöhen-Wendland, Elm-Lappwald, Harz, Lüneburger Heide, Münden, Terra.vita, Solling-Vogler, Lake Steinhude, Südheide, Weser Uplands, Wildeshausen Geest, Bourtanger Moor-Bargerveen.
linking to primary rather than secondary sources and prioritizing stable sites avoiding links that point to resources on researchers' personal pages using clean URLs or otherwise employing URL normalization or URL canonicalization using permalinks and persistent identifiers such as ARKs, DOIs, Handle System references, PURLs, or content addressing avoiding linking to documents other than web pages avoiding deep linking linking to web archives such as the Internet Archive, WebCite, archive.today, Perma.cc, Amber, or Arweave Strategies pertaining to the protection of existing links include:
==== Role in cardiac hypertrophy and fibrosis ==== Intracrine Ang II has been implicated in the development of cardiac hypertrophy, a process characterized by the enlargement of cardiac myocytes in response to increased workload or stress. Experimental models have shown that overexpression of non-secreted Ang II in cardiac cells leads to rapid hypertrophy independent of extracellular Ang II signaling. This suggests that intracellular Ang II plays a direct role in cardiomyocyte growth and structural remodeling. Similarly, intracrine Ang II contributes to myocardial fibrosis by upregulating profibrotic cytokines and growth factors, such as transforming growth factor-beta (TGF-β) and platelet-derived growth factor (PDGF). This promotes the excessive deposition of extracellular matrix proteins, leading to stiffening of the cardiac tissue and impaired cardiac function.
And here is The Mystery of the Yellow Room. That - ah, that is really a classic! I approve of it from start to finish. Such a logical approach! There were criticisms of it, I remember, which said it was unfair. But it is not unfair, my dear Colin. No, no. Very nearly so, perhaps, but no not quite. There is the hair's breadth of difference. No. All through there is truth, concealed with a careful and cunning use of words. Everything should be clear at that supreme moment when the men meet at the angle of the three corridors." He laid it down reverently. "Definitely a masterpiece, and, I gather, almost forgotten nowadays. In a 1981 poll by Edward D. Hoch of 17 mystery writers and reviewers, this novel was voted the third-best locked-room mystery of all time, behind Hake Talbot's Rim of the Pit (1944) and John Dickson Carr's The Hollow Man (1935). The popular 1946 Japanese detective novel The Honjin Murders (本陣殺人事件, Honjin satsujin jiken) by Seishi Yokomizo refers to The Mystery of the Yellow Room numerous times, the narrator quipping that Leroux's novel "bears the closest resemblance" to the story recounted in the novel. The final episode of the 2025 Netflix miniseries The Residence is titled The Mystery of the Yellow Room and concludes the series with a locked-room murder deduction.
=== Transistors === Both chemically controlled and voltage controlled graphene transistors have been built. Graphene-based transistors could be much thinner than modern silicon devices, allowing faster and smaller configurations. Graphene exhibits a pronounced response to perpendicular external electric fields, potentially forming field-effect transistors (FET), but the absence of a band gap fundamentally limits its on-off conductance ratio to less than ~30 at room temperature. A 2006 paper proposed an all-graphene planar FET with side gates. Their devices showed changes of 2% at cryogenic temperatures. The first top-gated FET (on–off ratio of <2) was demonstrated in 2007. Graphene nanoribbons may prove generally capable of replacing silicon as a semiconductor. A patent for graphene-based electronics was issued in 2006. In 2008, researchers at MIT Lincoln Lab produced hundreds of transistors on a single chip and in 2009, very high frequency transistors were produced at Hughes Research Laboratories. A 2008 paper demonstrated a switching effect based on reversible chemical modification of the graphene layer that gives an on–off ratio of greater than six orders of magnitude. These reversible switches could potentially be employed in nonvolatile memories. IBM announced in December 2008 graphene transistors operating at GHz frequencies. In 2009, researchers demonstrated four different types of logic gates, each composed of a single graphene transistor. In May 2009, an n-type transistor complemented the prior p-type graphene transistors.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.